Arbaclofen placarbil
Systematic (IUPAC) name | |
---|---|
(3R)-3-(4-chlorophenyl)-4-[[[(1S)-2-methyl-1-[(2-methylpropanoyl)oxy]propoxy]carbonyl]amino]butanoic acid | |
Clinical data | |
Pregnancy category |
|
Legal status |
|
Identifiers | |
CAS Number | 847353-30-4 |
ATC code | none |
PubChem | CID 11281011 |
ChemSpider | 9456008 |
KEGG | D08861 |
ChEMBL | CHEMBL2107312 |
Chemical data | |
Formula | C19H26ClNO6 |
Molar mass | 399.86 g/mol |
| |
|
Arbaclofen placarbil (ar-BAC-loe-fen pla-KAR-bil, also known as XP19986) is a prodrug of R-baclofen. Arbaclofen placarbil possesses more favorable pharmacokinetic profile than baclofen, with less fluctuations in plasma drug levels. It was being developed as a potential treatment for patients with GERD and spasticity due to multiple sclerosis; however, in May 2013 XenoPort announced the termination of development because of unsuccessful results in phase III clinical trials.[1]
See also
References
|
|
|
This article is issued from Wikipedia - version of the Saturday, April 02, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.